Real-time enrollment status for this myelodysplastic syndrome clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 8:44 AM UTC
| NCT Number | NCT04227847 |
| Recruiting Status | Recruiting |
| Condition | Myelodysplastic Syndrome |
| Phase | Clinical Trial |
| Target Enrollment | 178 participants |
| Active Locations | 49 sites in the US |
| Sponsor | Seagen, a wholly owned subsidiary of Pfizer |
| Last Updated on CT.gov | April 7, 2026 (Apr 7, 2026) |
As of July 13, 2026: Clinical trial NCT04227847 is currently recruiting participants. This clinical trial study for myelodysplastic syndrome is actively seeking new participants at 49 locations across the United States. The study is sponsored by Seagen, a wholly owned subsidiary of Pfizer. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04227847 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 49 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04227847 was last updated Apr 7, 2026 (April 7, 2026). HelloStudys verifies this status automatically.